The complement system in COVID-19: friend and foe?
- 6 August 2020
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (15)
- https://doi.org/10.1172/jci.insight.140711
Abstract
Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive health crisis. COVID-19–related morbidity and mortality have been attributed to an exaggerated immune response. The role of complement activation and its contribution to illness severity is being increasingly recognized. Here, we summarize current knowledge about the interaction of coronaviruses with the complement system. We posit that (a) coronaviruses activate multiple complement pathways; (b) severe COVID-19 clinical features often resemble complementopathies; (c) the combined effects of complement activation, dysregulated neutrophilia, endothelial injury, and hypercoagulability appear to be intertwined to drive the severe features of COVID-19; (d) a subset of patients with COVID-19 may have a genetic predisposition associated with complement dysregulation; and (e) these observations create a basis for clinical trials of complement inhibitors in life-threatening illness.This publication has 117 references indexed in Scilit:
- Complement and viral pathogenesisVirology, 2011
- Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63Journal of Virology, 2010
- Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodiesGlycobiology, 2008
- The Role of Complement in Inflammatory Diseases From Behind the Scenes into the SpotlightThe American Journal of Pathology, 2007
- Simultaneous Activation of Complement and Coagulation by MBL-Associated Serine Protease 2PLOS ONE, 2007
- Genomic view of the evolution of the complement systemImmunogenetics, 2006
- Complement Activation in Angiotensin II–Induced Organ DamageCirculation Research, 2005
- The role of C5a and antibody in the release of heparan sulfate from endothelial cellsEuropean Journal of Immunology, 1991
- Interferon gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture.The Journal of Experimental Medicine, 1988
- Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.JCI Insight, 1983